Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.45 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.45 |
| ▸ | ALOX15 | P16050 | 2/20 | 0.45 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.45 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.45 |
| ▸ | TSHR | P16473 | 1/20 | 0.45 |
| ▸ | NR1I2 | O75469 | 2/20 | 0.43 |
| ▸ | PTGS2 | P35354 | 2/20 | 0.43 |
| ▸ | ADORA3 | P0DMS8 | 2/20 | 0.43 |
| ▸ | PGR | P06401 | 1/20 | 0.43 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.43 |
| ▸ | CNR1 | P21554 | 1/20 | 0.43 |
| ▸ | CNR2 | P34972 | 1/20 | 0.43 |
| ▸ | F7 | P08709 | 3/20 | 0.42 |
| ▸ | F3 | P13726 | 3/20 | 0.42 |
| ▸ | CYP19A1 | P11511 | 3/20 | 0.42 |
| ▸ | MAPT | P10636 | 2/20 | 0.42 |
| ▸ | OXER1 | Q8TDS5 | 2/20 | 0.42 |
| ▸ | PTGS1 | P23219 | 2/20 | 0.42 |
| ▸ | PPARG | P37231 | 2/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL290120 | 1.00 | ALDH1A1 (0.45) | ALDH1A1CYP3A4ALOX15HSD17B10TDP1 | |
| SCHEMBL21052552 | 0.99 | ALDH1A1 (0.47) | ALDH1A1CYP3A4ALOX15HSD17B10TDP1 | |
| SCHEMBL23496246 | 0.99 | ALDH1A1 (0.47) | ALDH1A1CYP3A4ALOX15HSD17B10TDP1 | |
| SCHEMBL20574219 | 0.96 | ADORA3 (0.48) | ALDH1A1CYP3A4ALOX15HSD17B10TDP1 | |
| SCHEMBL23496243 | 0.96 | ADORA3 (0.48) | ALDH1A1CYP3A4ALOX15HSD17B10TDP1 | |
| SCHEMBL21052407 | 0.95 | ALDH1A1 (0.41) | ALDH1A1CYP3A4ALOX15HSD17B10TDP1 | |
| SCHEMBL21052406 | 0.95 | ALDH1A1 (0.41) | ALDH1A1CYP3A4ALOX15HSD17B10TDP1 | |
| SCHEMBL20574367 | 0.92 | ALDH1A1 (0.52) | ALDH1A1CNR1CNR2MAPT | |
| SCHEMBL3708103 | 0.91 | ADORA3 (0.40) | ALDH1A1CYP3A4ALOX15HSD17B10TDP1 | |
| SCHEMBL21052383 | 0.91 | ADORA3 (0.40) | ALDH1A1CYP3A4ALOX15HSD17B10TDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 42 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260000632-A1 | STRUCTURALLY MODIFIED FATTY ACIDS FOR IMPROVING GLYCEMIC CONTROL AND TREATING INFLAMMATORY BOWEL DISEASE | NORTHSEA THERAPEUTICS B V (NL) | 2026-01-01 | — | — | US | disclosed |
| US-12440466-B2 | Fatty acid derivatives for treating non-alcoholic steatohepatitis | BASF AS (NO) | 2025-10-14 | — | — | US | disclosed |
| EP-3720431-B1 | FATTY ACID DERIVATIVES FOR TREATING NON-ALCOHOLIC STEATOHEPATITIS | BASF AS (NO) | 2024-10-30 | — | — | EP | disclosed |
| US-20240325336-A1 | COMBINATION THERAPIES COMPRISING OXYGEN-CONTAINING STRUCTURALLY ENHANCED FATTY ACIDS FOR TREATMENT OF NON-ALCOHOLIC STEATOHEPATITIS | NORTHSEA THERAPEUTICS B.V. (NL) | 2024-10-03 | — | — | US | disclosed |
| US-20240156769-A1 | FATTY ACID DERIVATIVES FOR TREATING NON-ALCOHOLIC STEATOHEPATITIS | BASF AS (NO) | 2024-05-16 | — | — | US | disclosed |
| US-11925614-B2 | Fatty acid derivatives for treating non-alcoholic steatohepatitis | BASF AS (NO) | 2024-03-12 | — | — | US | disclosed |
| EP-4267124-A1 | COMBINATION THERAPIES COMPRISING OXYGEN-CONTAINING STRUCTURALLY ENHANCED FATTY ACIDS FOR TREATMENT OF NON-ALCOHOLIC STEATOHEPATITIS | Northsea Therapeutics B.V. (NL) | 2023-11-01 | — | — | EP | disclosed |
| WO-2022137125-A1 | COMBINATION THERAPIES COMPRISING OXYGEN-CONTAINING STRUCTURALLY ENHANCED FATTY ACIDS FOR TREATMENT OF NON-ALCOHOLIC STEATOHEPATITIS | NORTHSEA THERAPEUTICS B.V. (NL) | 2022-06-30 | — | — | WO | disclosed |
| US-20210290576-A1 | STRUCTURALLY MODIFIED FATTY ACIDS FOR IMPROVING GLYCEMIC CONTROL AND TREATING INFLAMMATORY BOWEL DISEASE | BASF AS (NO) | 2021-09-23 | — | — | US | disclosed |
| US-20210290576-A1 | STRUCTURALLY MODIFIED FATTY ACIDS FOR IMPROVING GLYCEMIC CONTROL AND TREATING INFLAMMATORY BOWEL DISEASE | BASF AS (NO) | 2021-09-23 | — | — | US | disclosed |
| US-20130046013-A1 | SALICYLATE FATTY ACID DERIVATIVES | HOVLAND RAGNAR (NO) | 2013-02-21 | — | — | US | disclosed |
| US-20120122940-A1 | POLYUNSATURATED FATTY ACIDS FOR THE TREATMENT OF DISEASES RELATED TO CARDIOVASCULAR, METABOLIC AND INFLAMMATORY DISEASE AREAS | PRONOVA BIOPHARMA NORGE AS (NO) | 2012-05-17 | — | — | US | disclosed |
| US-20120122940-A1 | POLYUNSATURATED FATTY ACIDS FOR THE TREATMENT OF DISEASES RELATED TO CARDIOVASCULAR, METABOLIC AND INFLAMMATORY DISEASE AREAS | PRONOVA BIOPHARMA NORGE AS (NO) | 2012-05-17 | — | — | US | disclosed |
| US-20120122940-A1 | POLYUNSATURATED FATTY ACIDS FOR THE TREATMENT OF DISEASES RELATED TO CARDIOVASCULAR, METABOLIC AND INFLAMMATORY DISEASE AREAS | PRONOVA BIOPHARMA NORGE AS (NO) | 2012-05-17 | — | — | US | disclosed |
| WO-2012059818-A1 | METHODS OF TREATMENT USING LIPID COMPOUNDS | PRONOVA BIOPHARMA NORGE AS (NO) | 2012-05-10 | — | — | WO | disclosed |
| EP-2427415-A1 | POLYUNSATURATED FATTY ACIDS FOR THE TREATMENT OF DISEASES RELATED TO CARDIOVASCULAR, METABOLIC AND INFLAMMATORY DISEASE AREAS | Pronova BioPharma Norge AS (NO) | 2012-03-14 | — | — | EP | disclosed |
| WO-2010128401-A9 | POLYUNSATURATED FATTY ACIDS FOR THE TREATMENT OF DISEASES RELATED TO CARDIOVASCULAR, METABOLIC AND INFLAMMATORY DISEASE AREAS | PRONOVA BIOPHARMA NORGE AS (NO) | 2011-12-08 | — | — | WO | disclosed |
| WO-2010128401-A9 | POLYUNSATURATED FATTY ACIDS FOR THE TREATMENT OF DISEASES RELATED TO CARDIOVASCULAR, METABOLIC AND INFLAMMATORY DISEASE AREAS | PRONOVA BIOPHARMA NORGE AS (NO) | 2011-12-08 | — | — | WO | disclosed |
| WO-2010128401-A1 | POLYUNSATURATED FATTY ACIDS FOR THE TREATMENT OF DISEASES RELATED TO CARDIOVASCULAR, METABOLIC AND INFLAMMATORY DISEASE AREAS | PRONOVA BIOPHARMA NORGE AS (NO) | 2010-11-11 | — | — | WO | disclosed |
| WO-2010128401-A1 | POLYUNSATURATED FATTY ACIDS FOR THE TREATMENT OF DISEASES RELATED TO CARDIOVASCULAR, METABOLIC AND INFLAMMATORY DISEASE AREAS | PRONOVA BIOPHARMA NORGE AS (NO) | 2010-11-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240156769-A1 | FATTY ACID DERIVATIVES FOR TREATING NON-ALCOHOLIC STEATOHEPATITIS | CPT1A, NR1H2, NR1H3 | ALDH1A1 154/4885CYP3A4 772/4885ALOX15 66/4885 |
| US-20120122940-A1 | POLYUNSATURATED FATTY ACIDS FOR THE TREATMENT OF DISEASES RELATED TO CARDIOVASCULAR, METABOLIC AND INFLAMMATORY DISEASE AREAS | FFAR2, FFAR3, FFAR1 | ALDH1A1 695/4885CYP3A4 1212/4885ALOX15 21/4885 |
| US-20260000632-A1 | STRUCTURALLY MODIFIED FATTY ACIDS FOR IMPROVING GLYCEMIC CONTROL AND TREATING INFLAMMATORY BOWEL DISEASE | GLP1R, FFAR3, IAPP | ALDH1A1 3334/4885CYP3A4 3395/4885ALOX15 42/4885 |
| US-20210290576-A1 | STRUCTURALLY MODIFIED FATTY ACIDS FOR IMPROVING GLYCEMIC CONTROL AND TREATING INFLAMMATORY BOWEL DISEASE | GLP1R, GPR119, FABP2 | ALDH1A1 1654/4885CYP3A4 3847/4885ALOX15 31/4885 |
| US-20240325336-A1 | COMBINATION THERAPIES COMPRISING OXYGEN-CONTAINING STRUCTURALLY ENHANCED FATTY ACIDS FOR TREATMENT OF NON-ALCOHOLIC STEATOHEPATITIS | ACACA, PC, ACACB | ALDH1A1 525/4885CYP3A4 1003/4885ALOX15 176/4885 |
| US-20130046013-A1 | SALICYLATE FATTY ACID DERIVATIVES | FASN, SCD, FABP2 | ALDH1A1 268/4885CYP3A4 1500/4885ALOX15 30/4885 |
| US-12440466-B2 | Fatty acid derivatives for treating non-alcoholic steatohepatitis | CPT1A, NR1H2, NR1H3 | ALDH1A1 154/4885CYP3A4 772/4885ALOX15 66/4885 |
| US-11925614-B2 | Fatty acid derivatives for treating non-alcoholic steatohepatitis | CPT1A, NR1H3, NR1H2 | ALDH1A1 162/4885CYP3A4 796/4885ALOX15 65/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.